Tempus AI, Inc. (TEM)

NMS – Real Time Price. Currency in USD

46.95

-1.51 (-3.12%)

At close: May 12, 2026, 4:00 PM EDT

46.96

+0.01 (0.02%)

After-hours: May 12, 2026, 7:59 PM EDT

11.05.2026

Ambry Genetics' CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced that its CARE Program (Comprehensive, Assessment, Risk, and Education) has been awarded “Best Overall Health Informatics Solution” in the 10th Annual MedTech Breakthrough Awards. The global program recognizes excellence in digital health and medical technology, selecting CARE from more than 5,000 nominations worldwide. The CA.

08.05.2026

Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine

Tempus AI, Inc. is positioned as a data-driven precision medicine leader, leveraging AI and a vast multi-modal patient database to drive diagnostics and biopharma partnerships. TEM's dual business model—genomic diagnostics and data licensing—creates network effects, with diagnostics feeding a proprietary data moat that underpins high-margin, scalable growth. Despite a 50% share price decline from highs and ongoing unprofitability, TEM's rising revenues, expanding gross margins, and robust contract pipeline support a strong buy rating for long-term investors.

08.05.2026

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the pricing of $400.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The ag.

07.05.2026

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its intent to offer, subject to market conditions and other factors, $350.0 million aggregate principal amount of Convertible Senior Notes due in 2032 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act.

07.05.2026

Tempus AI: Another Post-Earnings Dip Worth Buying

Tempus AI presents a compelling long-term opportunity, with strong data adoption and an expanding addressable market beyond Oncology. Q1 showed mixed results: robust Oncology testing, Hereditary weakness, decelerating revenue growth, but narrowing losses and gross margin expansion. Record $1.1B TCV and 126% net revenue retention underscore Tempus AI's durable value proposition and client stickiness.

06.05.2026

TEM Q1 Loss Narrower Than Expected, Revenues Beat, Stock Down

Tempus AI posts narrower Q1 loss and strong 36% revenue growth, but shares slide after-market as operating loss and rising costs weigh on sentiment.

06.05.2026

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer's disease. Through the agreement, Tempus AI will build a Tempus Next care gap program for Alzheimer's disease blood-based biomarker testing.

Videos

08.08.2025

Positive

TEM Earnings Rally: A.I. Use in Health Care, Drug Discovery

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
TEM	BTIG Research	Buy	undefined >> $60	April 21st 2025
TEM	JP Morgan	Neutral	$50 >> $55	February 25th 2025
TEM	William Blair	Market Perform	undefined >> undefined	February 12th 2025

Press releases

11.05.2026

Ambry Genetics' CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”

08.05.2026

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

07.05.2026

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its intent to offer, subject to market conditions and other factors, $350.0 million aggregate principal amount of Convertible Senior Notes due in 2032 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act.

06.05.2026

Tempus AI, Inc. (TEM)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Tempus AI, Inc. (TEM)

Ambry Genetics' CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”

Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

Tempus AI: Another Post-Earnings Dip Worth Buying

TEM Q1 Loss Narrower Than Expected, Revenues Beat, Stock Down

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Videos

Upgrades / Downgrades

Press releases

Ambry Genetics' CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Ambry Genetics' CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”

Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

Tempus AI: Another Post-Earnings Dip Worth Buying

TEM Q1 Loss Narrower Than Expected, Revenues Beat, Stock Down

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Videos

Upgrades / Downgrades

Press releases

Ambry Genetics' CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Search stocks

Tempus AI, Inc. (TEM)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Tempus AI, Inc. (TEM)

Ambry Genetics' CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”

Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

Tempus AI: Another Post-Earnings Dip Worth Buying

TEM Q1 Loss Narrower Than Expected, Revenues Beat, Stock Down

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Videos

Upgrades / Downgrades

Press releases

Ambry Genetics' CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Ambry Genetics' CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”

Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

Tempus AI: Another Post-Earnings Dip Worth Buying

TEM Q1 Loss Narrower Than Expected, Revenues Beat, Stock Down

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Videos

Upgrades / Downgrades

Press releases

Ambry Genetics' CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows